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Summary
Objective: To investigate the effects of intraarticular hyaluronic acid (HA) (Artzal, Seikagaku Corp., Japan) in geriatric participants with unilat-
eral knee osteoarthritis (OA).
Method: This was a prospective, observer-blind study with 6 months follow-up done in the setting of an outpatient rehabilitation department in
a university-afﬁliated tertiary care medical center. Sixty-eight patients, aged 65 years or above, with symptoms and radiographic evidence of
unilateral knee OA for at least 6 months were recruited. Patients received ﬁve weekly intraarticular injections of Artzal into symptomatic knees.
Fifty-six participants completed the study. Fifty age-, body mass- and gender-matched healthy individuals were selected as control. Visual
analog scale (VAS), Lequesne index and four balance tests including single-leg stance test (SLS), function reach test (FRT), timed ‘‘Up-
and-Go’’ test (TUG) and Berg balance scale (BBS) were assessed before injection and at each follow-up visit in the OA group. Four balance
tests were obtained on healthy participants for data comparison.
Results: Before Artzal injections, the OA group showed signiﬁcantly worse VAS, Lequesne index and four balance tests scores than did the
control group (P< 0.001). Signiﬁcant improvement in all outcome measures were noted at 1 week, 1, 3 and 6 months post the ﬁfth injection
compared with baseline before injection. Local adverse events were reported in four patients (7.1%).
Conclusion: Signiﬁcant improvement in pain, physical function and balance tests was demonstrated after ﬁve weekly Artzal injections in ge-
riatric patients with knee OA. The effect had rapid onset at 1 week and may last for 6 months.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) of the knee is a common chronic degen-
erative disorder, affecting 30e40% of the population by the
age of 65 years1. It is a major cause of locomotor disability
among the elderly2,3 and has been implicated as a risk fac-
tor for falls in older adults4. Current treatment options for
knee OA include the use of simple analgesics or nonsteroi-
dal antiinﬂammatory drugs (NSAIDs), glucosamine and
chondroitine sulphate, intraarticular corticosteroid injec-
tions, physical therapy, weight reduction, orthotics and sur-
gical treatment ranging from arthroscopy to total knee
replacement5. Since there is no curative therapy for OA,
the most pressing need for the majority of patients with
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and improve function6.
Intraarticular hyaluronic acid (HA) is a relatively new op-
tion for improving pain and articular function and has gained
popularity in the treatment of knee OA. Several trials have
attempted to evaluate the effect of intraarticular HA in OA
of the knee7e15. Conﬂicting conclusions regarding efﬁcacy
have been observed among studies and it is not clear
from these studies whether elderly populations respond
well to HA therapy. In addition, no study to date has as-
sessed whether balance function would change in geriatric
OA individuals after HA injections.
Balance impairments are associated with an increased
risk of falls and poorer mobility measures in the elderly pop-
ulation16. The presence of knee OA may accelerate the de-
terioration of balance control systems or compound the
effects of aging. However, studies that evaluated balance
in people with knee OA are limited17e19. Hassan et al.18
and Wegener et al.19 demonstrated increased postural
sway in subjects with knee OA when standing on a ﬁrm sur-
face in both AP and lateral directions. In contrast, Hurley
et al.17 were unable to detect a deﬁcit in body sway in indi-
viduals with OA, despite the OA group being more unsteady6
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lized force platforms. However, these expensive apparatus
are not readily available to the majority of clinicians in the
clinical setting. Furthermore, falls and loss of balance
most commonly occur during dynamic tasks such as walk-
ing. It is therefore important that the evaluation of balance
incorporates testing procedures that reﬂect the dynamic na-
ture of locomotor tasks20,21. In this study, simple, inexpen-
sive and easy-to-administer clinical tests were used to
assess both static and dynamic balance.
The purpose of this study was to determine the efﬁcacy of
ﬁve weekly intraarticular injections of HA in geriatric partic-
ipants with unilateral knee OA. Pain as documented via
visual analog scale (VAS), functional parameters including
Lequesne index, and clinical tests of balance by using
four simple and easy measures were evaluated.
Methods
PARTICIPANTS
The study was approved by the institutional review board
for human investigation and all subjects provided signed in-
formed consent before being enrolled in the study. Partici-
pants were divided into two groups: those with OA and
the non-OA healthy control. The group with OA consisted
of 68 participants, aged 65 and older, with unilateral symp-
tomatic knee OA for at least 6 months. Fifty age-, body
mass- and gender-matched healthy individuals without
knee OA were selected as the control group. Subjects
with a history of arthritis, major trauma to the lower limbs,
history of prolonged knee pain in the past year, or display-
ing abnormality on physical examination of the knee (effu-
sion, palpable warmth, ligamentous laxity, etc.) were
excluded from the control group. X-rays of bilateral knees
were performed to exclude asymptomatic knee OA accord-
ing to the Ahlba¨ck grading system22.
The inclusion criteria for the group with OA included uni-
lateral knee pain with no improvement after conservative
treatment for at least 6 months, average pain on knee
movement of at least 3 cm on a 10-cm VAS at the time of
inclusion, grade I or II tibiofemoral OA of the knee according
to the Ahlba¨ck grading system based on weight-bearing an-
teroposterior and lateral knee radiographs taken within the
previous 6 months22 (grade I¼ joint space narrowing
<3 mm; grade II¼ joint space obliterated or almost obliter-
ated). Knee radiographs were reviewed by one of the
authors.
Exclusion criteria included previous orthopedic surgery
on the spine or lower limbs, knee instability or marked defor-
mity on examination, intraarticular steroid or HA injection
within the past 6 months, history of rheumatoid arthritis,
gout, recurrent pseudogout or any other inﬂammatory ar-
thropathy, and presence of severe neurological, cardiac,
psychiatric disorders or other speciﬁc conditions (neoplasm,
diabetes mellitus, recent trauma, severe dizziness, visual
deﬁcit, etc.) that would interfere with the clinical assessment
during the study period.
OUTCOME MEASURES
The patient rated the intensity of pain with regard to aver-
age pain on knee movement over the previous week using
a 10-cm horizontal VAS23. The VAS was marked in 1-cm in-
crements with the descriptors ‘‘no pain’’ and ‘‘worst pain’’ at
either end. Subsequent recordings of VAS were done onseparate sheets of paper. This prevented the subjects
from comparing the present VAS with the previous one.
Lequesne index was used to assess severity of knee
symptoms during the last week24. It is validated and in-
cludes the measurement of pain (5 items), walking distance
(2 items), and activities of daily living (4 items). Maximal
score is 24 and higher scores represent worse function.
Single-leg stance test (SLS) is done by raising one foot
up without touching it to the supported lower extremity
with knee OA and maintain balance for as long as possible.
Failure occurs if the stance foot shifts in any way or the non-
stance foot touches the ground. In our study, each partici-
pant performed three trials, and the best result of the
three trials was recorded25. SLS time of <30 s in an older
ambulatory outpatient population is associated with a higher
risk of falling26.
The functional reach test (FRT) is used to screen for bal-
ance abilities27. The test evaluates how far a participant can
reach forward beyond arm’s length while maintaining a ﬁxed
base of support in the standing position. Three measure-
ments were obtained in our study, and an average of the
three measurements was taken as the ﬁnal measurement.
Validity of data for the FRT was demonstrated by a signiﬁ-
cant correlation (r¼ 0.71) with laboratory center of pressure
measurements in a study of 128 people (aged 21e87
years)27. Functional reach is a measure of the anterior limit
of stability. A longer functional reach suggests that partici-
pants have a larger anterior margin of stability, hence better
dynamic balance control.
Timed ‘‘Up-and-Go’’ test (TUG) is a simple test of basic
physical functional mobility for frail elderly persons with
high interrater reliability and content reliability28. A patient
is asked to rise from an armchair, walk 3 m at a safe and
comfortable pace, turn around, walk back to the chair,
and sit down again. The whole procedure is demonstrated
ﬁrst before the actual test. The score is the time in seconds
it takes to complete these tasks. It also predicts whether
a patient can walk safely alone outside28.
Berg balance scale (BBS) is a 56-point scale to evaluate
performance during 14 common activities, such as stand-
ing, turning, and reaching for an object on the ﬂoor. The
BBS examines static and dynamic balance with progressing
difﬁculty from sitting to single-leg standing. Higher scores
correspond to better balance. It has high interrater and in-
trarater reliability. Although it is designed to be used as
a clinical assessment tool, scores on the BBS have been
shown to correlate with laboratory tests of balance29.
STUDY DESIGN
This was a prospective, observer-blind controlled study
designed to examine the efﬁcacy of intraarticular HA on re-
ported pain, functional ability and clinical balance tests in el-
derly individuals with unilateral OA of the knee.
Baseline characteristics (age, sex, weight, height and
body mass index) were recorded in all participants. Before
the ﬁrst injection, participants in the OA group completed
baseline measures including VAS, the Lequesne index,
and four balance tests including SLS, FRT, TUG and
BBS. The control group also completed four balance tests
for data comparison. SLS and TUG tests were measured
on a stopwatch to the nearest 1/100 of a second. The order
of testing was as follows: SLS, FRT, TUG and BBS with
3 min rest between each test.
The OA patients were given ﬁve weekly intraarticular in-
jections of HA (Artzal, 2.5 ml injection, 1% hyaluronan, av-
erage molecular weight 900 kDa) by the same physician
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aspirated before injecting. Follow-up assessments were
made at intervals of 1 week, 1, 3 and 6 months after the ﬁfth
injection. The different physician who was responsible for
the evaluation of the participants remained unaware of
each participant’s group and treatment throughout the entire
study. Patients taking analgesics or NSAIDs stopped them
at least 7 days prior to the ﬁrst assessment. During the study
period, no regular analgesics, NSAIDs or physical therapy
for knee joint conditions were permitted. Acetaminophen
(500 mg), up to 4 g/day was allowed as rescue medication.
If the treatment dose was above the stipulated limit (acet-
aminophen 4 g/day), the patient was regarded as a clinical
failure. The administration of all analgesic medication dur-
ing the study period was recorded on a diary card by the
patient.
To monitor the safety of each injection, the occurrence of
systemic and local adverse events, deﬁned as any un-
wanted events whether it was thought to be related to the
study drugs or not, were recorded.
STATISTICAL ANALYSIS
All statistical procedures were conducted with the Statis-
tical Package for the Social Sciences (version 12.0; SPSS
Inc., Chicago, Illinois). The data were presented as mean
standard deviation and independent t-tests were used to
compare differences between the OA group and the control
group. Baseline characteristic of sex was compared using
the chi-square test. Change of outcome measures in
VAS, Lequesne index, FRT, TUG and BBS were assessed
using paired t-test comparing baseline value with each
follow-up score. Changes in SLS were analyzed using
Wilcoxon signed rank test. P values of less than 0.05
were regarded as signiﬁcant.
Results
Sixty-eight geriatric OA patients were recruited in the
study. Five patients withdrew from the study before the ﬁnal
injection (two moving to another city and three because of
trafﬁc accident and unrelated intercurrent illness). Seven
patients were lost to follow-up because of noncompliance
and missing the scheduled appointments. Fixty-six OA par-
ticipants (21 females, 35 males) with an average age of
74.7 5.4 years (range 65e84 years) completed the study.
Fifty healthy participants (19 females, 31 males) with an
average age of 73.8 5.5 years (range 65e83 years)
were selected as the control group. Baseline characteristics
of all participants are presented in Table I. Groups were not
different in age, sex, weight, height and body mass index.
Table II provides a summary of outcome measures. The
group with knee OA before Artzal injections showed signif-
icant worse scores in SLS, FRT, TUG and BBS than did the
control group (P< 0.001). Compared with baseline ﬁndings,
results of VAS, Lequesne index and four balance tests im-
proved signiﬁcantly in all of our OA patients after the com-
pletion of ﬁve weekly injections. These effects were rapid
at 1 week after the ﬁfth injection, and the treatment effects
could last for at least 6 months.
Mean values of differences between baseline and postin-
jection follow-up scores at each time point are shown in
Table III. The mean VAS value reduced from 5.4 2.4 cm
at baseline to 3.1 1.7 cm at 1 week after the ﬁfth injection
(mean reduction¼ 2.3 cm) (P< 0.001) (Table II). The mean
reduction was 2.8 cm at 1 month and 3.0 cm at 3 months.The reduction still remained signiﬁcant at 6 months follow-
up P< 0.001) (Table III). The Lequesne index score re-
duced from 10.3 3.7 prior to injections to 7.2 3.8 at 1
week after the ﬁfth injection (P< 0.001). A considerable re-
duction to 5.9 3.3 and 5.7 3.5 were noted at 1 month
and 3 months (P< 0.001 and P< 0.001, respectively, com-
pared with baseline), and the beneﬁt persisted up to 6
months (P< 0.001) (Table II). Treatment with intraarticular
Artzal also improved balance function as assessed by
SLS, FRT, TUG and BBS tests. Each result remained sig-
niﬁcantly better than baseline at the postinjection 1-week
follow-up (P< 0.001 for each test) and the improvement
also remained signiﬁcant at 6 months follow-up (P< 0.001
for each test) (Table III).
Local adverse events with transient pain at injection site
and local warmth and swelling with varying intensities
were reported in four patients (7.1%). No severe or sys-
temic adverse events were observed in the participants dur-
ing the study.
OA patients who received intraarticular injections used
much less analgesics. The demand for analgesics (acet-
aminophen) fell from an average of 14 tablets weekly at
baseline to 4, 3, 3 and 3 tablets weekly at 1 week, 1, 3
and 6 months postinjection, respectively (P< 0.001 com-
pared with baseline) (Table II).
Discussion
The purpose of this study was to evaluate efﬁcacy of in-
traarticular HA on reported pain, functional ability and clini-
cal tests of balance in elderly individuals with unilateral OA
of the knee.
Various studies with HA had also used the Lequesne in-
dex score to quantify joint function, while VAS had been
proved to supply reliable data in the documentation of
pain levels23,24. Pietrogrande and Turchetto12 showed
a pain reduction 60 days after the intraarticular injections
of HA from VAS values of 6 cm down to 2 cm. According
to a recent review, intraarticular injection of HA reduced
knee pain in patients with OA by 20e40% over 6e12
months13. Di Marco and Letizia14 analyzed pain on weight
bearing following treatment with HA and they found a reduc-
tion of the pain level from 6.7 cm to 4.7 cm. It appeared that
the described pain relief as in the previous studies was also
documented in our study.
The functional analysis as deﬁned by Lequesne in past
studies with HA documented improved scores by about 4
points with a follow-up of 1 year8,15. Lequesne deﬁned ef-
fective treatment forms as those leading to a score
Table I
Baseline characteristics of all participants
Characteristics Knee OA
group
(n¼ 56)
Control
group
(n¼ 50)
P value
Age (years) 74.7 5.4 73.8 5.5 0.503
Sex (F/M) 21/35 19/31 0.800
Weight (kg) 68.2 8.8 67.4 8.2 0.699
Height (cm) 158.3 5.6 157.9 5.9 0.743
BMI (kg/m2) 27.3 4.1 27.2 4.0 0.892
OA knee (Lt/Rt) 25/31
Ahlba¨ck classiﬁcation
Grade I 26 0
Grade II 30 0
Disease duration (years) 5.3 4.7
Data are mean standard deviation; BMI¼ body mass index.
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Summary of outcomes before and after treatment
OA knee group (n¼ 56) Control group
(n¼ 50)
Baseline 1 week 1 month 3 months 6 months P value
VASy 5.4 2.4 3.1 1.7 2.7 1.5 2.4 1.3 2.5 1.5 AB* AC* AD* AE*
Lequesne indexy 10.3 3.7 7.2 3.8 5.9 3.3 5.7 3.5 5.7 3.2 AB* AC* AD* AE*
SLS 23.94 41.40 34.1 47.47 34.79 47.34 38.18 46.59 38.12 46.60 AB* AC* AD* AE* AF* 50.42 42.31
FRT 22.80 4.78 25.60 4.84 26.56 4.77 25.56 4.11 25.67 4.42 AB* AC* ADþ AE* AF* 28.81 4.31
TUGy 12.90 5.01 11.04 3.81 9.40 2.46 9.19 2.75 9.24 2.60 AB* AC* AD* AE* AF* 9.14 2.65
BBS 50.03 5.38 52.25 3.68 52.94 3.08 53.14 3.27 53.14 3.01 AB* AC* AD* AE* AF* 53.20 3.11
Acetaminophen
(tablets/week)
14.3 2.4 4.1 2.3 3.4 2.1 3.1 2.3 3.3 2.2 AB* AC* AD* AE*
Note: Values are the mean standard deviation; VAS¼ visual analogue scale; SLS¼ single-leg stance test; FRT¼ function reach test;
TUG¼ timed ‘‘Up-and-Go’’ test; BBS¼Berg balance scale.
The possible range for the VAS score was 0e10; the possible range for the Lequesne index was 0e24; and the possible range for the BBS
score was 0e56.
AB is the comparison for the OA group before and 1 week after the intraarticular hyaluronate injections; AC is the comparison for the OA
group before and 1 month after the intraarticular hyaluronate injections; AD is the comparison for the OA group before and 3 months after the
intraarticular hyaluronate injections; AE is the comparison for the OA group before and 6 months after the intraarticular hyaluronate injections;
and AF is the comparison for the OA group before injection with control group.
*P< 0.001 vs baseline; þP¼ 0.001 vs baseline.
yHigher scores represent worse pain or function.improvement of 30e40% at the time of follow-up30. In our
study, the reduction of the Lequesne index scores from
10.3 3.7 points at baseline to 5.7 3.2 points at 6 months
follow-up represented an improvement of 44.7%, which was
above the upper end of the values used to deﬁne treatment
effectiveness. Therefore, using the Lequesne criteria, the
intraarticular administration of HA can be deﬁned as an ef-
fective therapeutic measure in the treatment of geriatric
knee OA.
It is not clear whether elderly populations respond well to
intraarticular HA. In a previous study by Lohmander et al.8,
a subgroup analysis suggested that patients aged 60 years
or above with a baseline Lequesne index above 10 and ra-
diographically veriﬁed OA of the knee (Ahlba¨ck grade I or II)
showed signiﬁcant beneﬁt from intraarticular treatment with
HA. The study by Wobig et al.11 also showed improvement
after HA treatment in patients over 60 years old. In a meta-
analysis, patients older than 65 years of age and those with
the most advanced radiographic stage of OA (complete loss
of the joint space) were less likely to beneﬁt from intraartic-
ular injection of HA31. In our study, we demonstrated that
patients older than 65 years of age with radiographically
veriﬁed OA of the knee (Ahlba¨ck grade I or II) could beneﬁt
from intraarticular injections of HA.
To our knowledge, this was the ﬁrst study that examined
the effect of intraarticular injection of HA on balance. Poorer
balance test scores were demonstrated in the geriatric OAparticipants compared with non-OA healthy participants by
using simple clinical tests in our study. The close matching
of control participants in our study supported that the ob-
served balance deﬁcits were due to the presence of knee
OA, and not due to inherent differences between groups
with regard to age, gender or body mass index. Signiﬁcant
improvement in clinical balance tests was shown in addition
to pain reduction and improvement in physical function.
These effects were rapid at 1 week and could last for at
least 6 months.
Balance is an important component of performance for
transfer, ambulatory tasks and many activities of daily living.
Several potential mechanisms may be responsible for the
balance deﬁcits observed within the geriatric OA partici-
pants. Previous investigators have demonstrated that vi-
sion, peripheral proprioception and lower limb muscle
strength appear to be important determinants of balance
in the elderly32,33. Individuals with knee OA display reduc-
tions in quadriceps strength and activation as well as im-
pairments in knee joint proprioception17,34e37. These
deﬁcits, in combination with the aging process, may culmi-
nate in greater impairments in balance in this elderly OA
population, compared with their age-matched healthy coun-
terparts. Pain associated with knee OA may also play a role
in balance impairments. Messier et al.38 reported that adults
aged 65 years or older with chronic knee pain experienced
signiﬁcant declines in balance and lower extremity strengthTable III
Mean change from baseline in VAS, Lequesne index, SLS, FRT, TUG and BBS
VASy Lequesne indexy SLS FRT TUGy BBS
1 week 2.3 2.0* 3.1 2.1* 10.16 16.99* 2.80 3.90* 1.87 2.67* 2.2 2.9*
1 month 2.8 1.8* 4.4 2.0* 10.84 16.97* 3.75 3.99* 3.51 3.12* 2.9 3.4*
3 months 3.0 1.9* 4.6 1.5* 14.24 19.46* 2.75 4.53þ 3.71 3.18* 3.1 2.8*
6 months 2.9 2.2* 4.6 2.1* 14.18 20.26* 2.86 4.28* 3.66 3.13* 3.1 2.9*
VAS¼ visual analog scale; SLS¼ single-leg stance test; FRT¼ function reach test; TUG¼ timed ‘‘Up-and-Go’’ test; BBS¼Berg balance
scale. The possible range for the VAS score was 0e10; the possible range for the Lequesne index was 0e24; the possible range for the BBS
score was 0e56.
*P< 0.001 vs baseline; þP¼ 0.001 vs baseline.
yHigher scores represent worse pain or function.
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duce knee extensor and ﬂexor strength, which could com-
promise effective and timely motor responses in postural
control39. Furthermore, pain may result in reduced loading
of the affected joint40, potentially jeopardizing an individu-
al’s ability to maintain their center of mass within the base
of support. The mechanisms by which HA mediate its clin-
ical beneﬁt seem to be multifactorial and biologically re-
lated. More researches to study the impact of knee OA on
balance and the effects of HA on the joint may allow possi-
ble mechanisms of disability in the OA population to be elu-
cidated, and may permit more effective management of
patients with this disease.
The study had several limitations. A limitation of this study
included the absence of a control group. The placebo ef-
fects associated with joint injection were therefore not in-
vestigated. We did not make use of a saline control group
since saline injection could not be excluded as a source
of a noxious stimulus and it was inappropriate to subject
these symptomatic OA patients to a placebo. The number
of participants studied was small and they were not blinded
in treatment. OA participants were recorded by age, gender,
body weight and body mass index. They were not analyzed
on the basis of severity of OA, preinjection or postinjection
functional levels and assistive devices’ usage. In future
studies, we would like to recruit OA patients with a higher
Ahlba¨ck scale grade (i.e., IIIeV), to see whether intraarticu-
lar HA injections can improve balance function in severely
obliterated knee joints. The more precise identiﬁcation of
subgroups of patients who would most beneﬁt from this
treatment, as well as the role for repeated series of injec-
tions, must be clariﬁed in the future. A longer, longitudinal
study with a larger sample size is required to determine
whether viscosupplementation could attenuate balance
decline in the geriatric patients with knee OA and more
researches are needed to investigate whether viscosupple-
mentation can improve balance to a level that would
substantially reduce fall risk.
Conclusion
On the basis of this prospective, single-blind controlled
study of geriatric patients with unilateral knee OA (Ahlba¨ck
grading scale of stages I and II), we concluded that ﬁve
weekly intraarticular injections of HA produced a pro-
nounced reduction in pain, signiﬁcant improvement in phys-
ical function and clinical tests of balance. It was a useful and
well-tolerated treatment for knee OA, with rapid onset of ac-
tion at 1 week after the ﬁfth injection and the treatment ef-
fects could last for 6 months.
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